2026 VJC H2 Econs P1 Prelim ANS
Uploaded by ohnoe · 7 November 2026
VJC 2026 prelim set
- P1 QP
- 2026 VJC H2 Econs P1 Prelim ANSyou're here
- P2 QP
- P2 MSanswers
Preview
Text from the first pagesVJC 2026 JC2 H2 Economics Preliminary Examination – 9570 / 01 (CSQs) Suggested Answers and Markers’ Comments Question 1: Obesity drugs – elixir or illusion? Table 1: Adult obesity rates and healthcare expenditure in Singapore & the UK (2019–2024) Indicator Country 2019 2020 2021 2022 2023 2024 Adult Obesity Rate (%) (BMI ≥ 30 kg/m²) Singapore 12.7 13.5 14.2 15.0 15.9 16.8 United Kingdom 28.1 28.3 28.6 28.8 29.0 29.2 Government Health Spending (% of GDP) Singapore 2.28 3.42 3.13 2.6 2.63 — United Kingdom 7.96 10.18 10.12 9.11 8.99 — Total Health Spending (% of GDP) Singapore 4.41 5.70 5.15 4.33 4.49 — United Kingdom 9.98 12.10 12.08 11.10 10.99 — Extract 1: Wegovy maker forecasts sharp drop in revenue Medicines that enable dramatic weight loss are likely to experience a new boom in uptake, experts have said, as the first generic versions hit the market this week at a lower cost than the original drugs. The injections, dubbed “skinny jabs” by the media, can help people lose more than 10% of their body weight and have become hugely popular in recent years, with celebrities lauding their effects. Original brand name treatments include Wegovy and Saxenda, which are licensed for weight loss, and Ozempic and Victoza which are licensed for type 2 diabetes but are often prescribed “off-label” as a weight-loss aid. All four mimic a gut hormone called GLP-1 and are produced by the Danish pharmaceutical company Novo Nordisk. Now, cheaper generic versions are entering the market from a range of companies, such as Teva Pharmaceutical Industries, Hikma Pharmaceuticals, Pfizer, Viatris, and Sandoz. Despite the soaring popularity of these treatments, the landscape for key producers is shifting rapidly. Novo Nordisk has predicted a sharp drop in revenue in 2026 owing to what its boss described as a “painful” push by Donald Trump to lower US weight-loss drug prices, rising competition, and the loss of important patent protections. Denmark’s Novo, once the poster child for the growth in weight-loss treatments, said that the company’s sales revenue this year was likely to fall between 5% and 13%, ending years of double-digit gains. Mike Doustdar, the chief executive, pointed to Novo’s agreement with the Trump administration to cut prices heavily, from more than US$1,000 a month (£730) to an average price of US$350 (£255), and the patent expiry of semaglutide, the main ingredient of its obesity and diabetes drugs, in several countries including India. Source: Adapted from The Guardian, 25 June 2024 and The Guardian, 4 February 2026 1
VJC 2026 JC2 H2 Economics Preliminary Examination – 9570 / 01 (CSQs) Suggested Answers and Markers’ Comments Extract 2: Unemployed could be given weight-loss jabs to get back to work New weight-loss jabs could be given to unemployed people to help them get back into work, Wes Streeting has suggested. The health secretary said “widening waistbands” were placing a burden on the National Health Service (NHS). The latest generation of weight-loss medications could be administered to people to get them back into employment, and to ease costs to the health service, he added. The health secretary wrote, “Our widening waistbands are also placing significant burden on our health service, costing the NHS £11 billion a year – even more than smoking. And it’s holding back our economy. Illness caused by obesity causes people to take an extra four sick days a year on average, while many others are forced out of work altogether.” “The long-term benefits of these drugs could be monumental in our approach to tackling obesity. For many people, these weight-loss jabs will be life-changing, help them get back to work, and ease the demands on our NHS.” Health economists note that beyond individual health improvements, widespread use of weight-loss drugs generates significant positive spillovers for society, such as higher workplace productivity, reduced burden on public health infrastructure, and fiscal savings. However, Streeting said individuals would still need to remain responsible for taking “healthy living more seriously”, as the “NHS can’t be expected to always pick up the tab for unhealthy lifestyles”. Source: The Guardian, 15 October 2024 Extract 3: Weight-loss drugs alone will not solve UK’s obesity crisis Weight-loss drugs cannot rescue the UK from its deepening obesity crisis, the government’s chief medical adviser has said. Prof Chris Whitty delivered a critique of the drugs during a speech in London on Thursday evening. “Just relying on the drugs seems to me the wrong answer,” he said. His scepticism about drugs such as Wegovy, known as GLP-1 agonists, contrasted with the health secretary, Wes Streeting, who has hailed them as a “real gamechanger” in tackling obesity. Whitty cautioned against relying too much on the drugs to treat obesity. Tougher action to curb junk food advertising and make food healthier to prevent obesity occurring would be a better course of action to take, he said. “Does anyone in this group believe that the correct answer is to allow obesity to rise because of aggressive marketing of junk food to children and then stick them on GLP-1 agonists at the age of 18? I think it is shocking if that is where we end up.” “GLP-1s, they are very good drugs. [But] we know that if you stop them, the weight comes on again. Further, GLP-1s have been shown to increase the risk of complications such as severe acute pancreatitis and sudden sight loss. With weight regain common after coming off GLP-1s, people could end up in older age with less muscle mass and more fat than before they began taking them.” Katharine Jenner, the director of the Obesity Health Alliance, said: “It is not a commonsense approach for the government to continue to let children grow up in environments flooded with unhealthy options, only to rely on medicines later in life to address the harm. We should not accept a system where the food industry drives obesity, and the pharmaceutical industry is
Content continues in the PDF. Download PDF
